New treatment for moderate to severe atopic dermatitis shows promising long-term results

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

Keep talking: Disgraced crypto king's high-risk strategy

Omnipresent on talk shows and conference panels, disgraced cryptocurrency tycoon Sam Bankman-Fried is defying the advice of the legal profession and staying in the public eye despite facing the real threat of prosecution and even jail time.

source https://www.lifetechnology.com/blogs/life-technology-technology-news/keep-talking-disgraced-crypto-kings-high-risk-strategy